The import of antisera and other blood fractions to France is forecasted to rise steadily from 2024 through 2028. Starting at $4.84 billion in 2024, the figures anticipate growing to $5.46 billion by 2028. The year-on-year growth rate maintains a moderate increase, reflecting a stable demand in France for these medical products compared to the previous year. The compound annual growth rate (CAGR) for the five-year period suggests a consistent demand for imported antisera and blood derivatives in the French market.
Key future trends to watch include potential shifts in global healthcare practices, the impact of price fluctuations in raw materials, regulatory changes in the pharmaceutical industry, and technological advancements in related medical treatments that might affect demand and supply dynamics.
